Klus Pharma Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Phase 2

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: SKB264
Drug: Osimertinib
Drug: Pembrolizumab
Drug: Carboplatin

First Posted Date: 2023-04-18

Last Posted Date: 2024-07-31

Lead Sponsor: Klus Pharma Inc.

Target Recruit Count: 278

Registration Number: NCT05816252

Locations: 🇦🇺
St Vincent's Hospital - Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China

and more 63 locations

SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

Phase 2

Recruiting

Conditions: Solid Tumor

Interventions: Drug: SKB264
Drug: Pembrolizumab

First Posted Date: 2022-12-08

Last Posted Date: 2024-12-19

Lead Sponsor: Klus Pharma Inc.

Target Recruit Count: 240

Registration Number: NCT05642780

Locations: 🇺🇸
Community Clinical Research Center, Anderson, Indiana, United States
🇺🇸
Westchester Medical Center, Hawthorne, New York, United States
🇺🇸
Texas Oncology, P.A. Austin, TX, Austin, Texas, United States

and more 43 locations

Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Phase 1

Recruiting

Conditions: Non-Small Cell Lung Cancer
Breast Cancer
Head and Neck Squamous Cell Carcinoma
Epithelial Ovarian Cancer
Gastroesophageal Junction Adenocarcinoma
Urothelial Carcinoma
Small-Cell Lung Cancer
Gastric Adenocarcinoma
Endometrial Carcinoma

Interventions: Drug: SKB264

First Posted Date: 2019-11-05

Last Posted Date: 2024-06-24

Lead Sponsor: Klus Pharma Inc.

Target Recruit Count: 1300

Registration Number: NCT04152499

Locations: 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸
Florida Cancer Specialists & Research Institute, Lake Mary, Florida, United States
🇺🇸
BRCR Medical Center, Inc, Plantation, Florida, United States

and more 121 locations

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Phase 1

Completed

Conditions: HER-2 Gene Amplification
Salivary Gland Tumor
Lung Cancer
Rare Diseases
Head and Neck Cancer
Bile Duct Cancer
Prostate Cancer
Recurrent Prostate Cancer
Rectal Cancer
Rectal Cancer Stage III

Interventions: Drug: A166

First Posted Date: 2018-07-26

Last Posted Date: 2023-08-03

Lead Sponsor: Klus Pharma Inc.

Target Recruit Count: 49

Registration Number: NCT03602079

Locations: 🇺🇸
Florida Cancer Specialists & Research Institute, Sarasota, Florida, United States
🇺🇸
Mary Crowley Cancer Research Centers - Medical City, Dallas, Texas, United States
🇺🇸
Stephenson Cancer Center, Oklahoma City, Oklahoma, United States

and more 7 locations

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy